AddedRisk Factors
These actions have resulted, and are expected to further result, in retaliatory measures on U.S. goods by other foreign governments. If maintained, these recently announced tariffs, and the potential escalation of trade disputes could pose a risk to our business that could further affect our financial condition or results of operations and/or cash flows, as well as, our long-term investment strategies. The extent and duration of the tariffs and the resulting impact on general economic conditions and on our business are uncertain and are expected to be impacted by various factors, such as negotiations between U.S. and affected countries, the responses of other countries or regions, exemptions or exclusions that already exist or may be granted, availability and cost of alternative sources of our products and materials, and our ability to offset the effects of any tariffs that might be imposed.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer’s decision. The FDA may not agree with our decisions regarding whether new clearances or approvals
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
are necessary. We have modified certain of our products subsequent to obtaining 510(k) clearance, and have determined based on our review of the applicable FDA guidance that in these instances new 510(k) clearances or pre-market approvals were not required. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or PMAs for modifications to our products or any other product for which we may obtain 510(k) clearance in the future, and for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. On April 4, 2025, we received a warning letter from the FDA regarding certain modifications we made to our cleared MedFusion™ Model 4000 Syringe Infusion Pump and CADD™ Solis VIP Ambulatory Infusion Pump, and since then we are working closely with the FDA to resolve all concerns identified in such warning letter, including the filing of new clearances for next generation MedFusion™ and a refreshed CADD™ Solis device (which are currently under review by the FDA), and though we believe we will be able to ultimately close out this warning letter, there is no guarantee that we will be able to do so in a timely manner, or that we will not receive similar notices in the future.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
Foreign data protection laws, including the European Union General Data Protection Regulation (the "EU GDPR") and the United Kingdom General Data Protection Regulation (the "UK GDPR") (the EU GDPR and UK GDPR together referred to as the "GDPR", may also apply to health-related and other personal data obtained outside of the U.S. or in the context of our establishments outside of the U.S.. The GDPR imposes strict requirements for processing the personal data of individuals within the EEA and the UK or in the context of our activities within the EEA and the UK, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose,
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedRisk Factors
tooling because its costs may not be recovered through production of saleable product, which could adversely affect our financial condition.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
applicable rules or regulations could lead to penalties and adversely impact our reputation, customer attraction and retention, access to capital and employee retention. Such sustainability and ESG matters may also impact our suppliers and customers, which may augment or cause additional impacts on our business, financial condition, or results of operations.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
For example, in September 2019, the FDA issued revised final guidance describing an optional "safety and performance based" pre-market review pathway for manufacturers of "certain, well-understood device types" to demonstrate substantial equivalence under the 510(k) clearance pathway by demonstrating that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA maintains a list of device types appropriate for the "safety and performance based pathway" and continues to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as recommended testing methods, where feasible. The FDA may establish performance criteria for classes of devices for which we or our competitors seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
The rules applicable in Great Britain differ from the EEA as a result of Brexit. On June 26, 2022, the Medicines and Healthcare Products Regulatory Agency (“MHRA”) published its response to a 10-week consultation on the future regulation of medical devices in the United Kingdom (“UK”). The MHRA proposes amendments to the UK Medical Devices Regulations 2002 (which are based on EU legislation, primarily the EU Medical Devices Directive), in particular to create new access pathways to support innovation, create an innovative framework for regulating software and artificial intelligence as medical devices, reform in vitro diagnostic regulation, and foster sustainability through the reuse and remanufacture of medical devices. The MHRA has stated that it continues its intention to implement the proposals from such consultation through secondary legislation. In addition, on November 14, 2024, the MHRA launched a new consultation on proposals to update the regulatory framework for medical devices in Great Britain, covering four topics, namely (1) a new international reliance scheme to enable swifter market access for certain devices that have already been approved in a comparable regulator country; (2) the new UK Conformity Assessed (“UKCA”) mark and, in particular, proposals to remove the requirement to place such UKCA marking on devices; (3) conformity assessment procedures for in vitro diagnostic devices; and (4) maintaining in UK law certain pieces of “assimilated” EU law which are due to sunset in 2025. The MHRA consultation was opened until January 5, 2025, and it is expected that secondary legislation implementing the proposals would be introduced in 2025. The divergence of the new UK rules from EU law could adversely affect or delay our ability to obtain approval for our products in the UK, which could adversely affect our ability to grow our business. See “Part 1, Item 1. Government Regulation - Regulation of Medical Devices in the European Union – Brexit and the UK Regulatory Framework.”
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Further, from January 1, 2021, companies have to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of €20 million (£17.5 million) or 4% of global turnover. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a data transfer mechanism from the UK to U.S. entities self-certified under the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” for a further discussion of the financial impact of exchange rate fluctuations on our results of operations. Fluctuations in currency exchange rates are caused by a number of factors that are beyond our control, including a country’s political and economic policies, inflationary conditions, disruptions in the financial markets, and global economic and geopolitical conditions.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
The Smiths Medical acquisition has resulted in significant growth in our personnel and operations, adding approximately 6,700 employees to our headcount at the time of acquisition. Our total headcount as of December 31, 2024 was approximately 15,000 employees. We have incurred and continue to incur significant expenditures and the allocation of management time to assimilate the Smiths Medical employees in a manner that preserves the key aspects of our corporate culture, including a focus on strong customer satisfaction, but there can be no assurance that we will be successful in our efforts. If we do not effectively integrate, train and manage our combined employee base and maintain strong customer
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
relationships, our corporate culture could be undermined, the quality of our products and customer service could suffer, and our reputation could be harmed, each of which could adversely impact our business, financial condition and results of operations.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•challenges in maintaining employee morale and retaining or attracting key employees;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
We As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we operate our business, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Specifically, this final rule, The QMSR, which replaced the FDA expects to go into effect on February 2, 2026, establishes FDA’s former Quality System Regulation, sets forth the “Quality Management System Regulation,” (“QMSR”), which FDA’s cGMP requirements for medical devices, and among other things, incorporates by reference certain elements of the quality management system requirements of ISO 13485:2016.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
A decline in the value of the local currency in relation to the U.S. dollar has in prior years adversely affected and may in future years adversely affect their ability to profitably sell in their market the products they buy from us, and has in prior years adversely affected and may in future years adversely affect their ability to make payment to us for the products they purchase.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, in June 2024, Smiths Medical ASD initiated Class 1 recalls with respect to certain tracheostomy tube kits, and, in May 2024, Smiths Medical ASD initiated Class 1 recalls for certain paraPAC plus ventilators, and in April 2025 and February 2025, we initiated Class 1 recalls for certain CADD Solis ambulatory infusion pumps and ProPort venous access systems and catheters, respectively.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
While we have not previously breached and are not currently in breach of these or any other covenants contained in our credit agreement, our ability to comply with these covenants may be affected by events beyond our control, including health crises and global pandemics, other geopolitical events, supply chain interruptions or general economic environment, including high inflation and interest rates.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
For the Smiths Medical acquisition, we used a significant portion of our cash on hand and incurred a substantial amount of debt to finance the cash consideration portion and certain other amounts paid in connection with the Smiths Medical acquisition, which could adversely affect our business, including by restricting our ability to engage in additional transactions or incur additional indebtedness.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
If our manufacturing facilities or those of any of our component suppliers are found to be in violation of applicable laws and regulations, or we or our suppliers have significant noncompliance issues or fail to timely and adequately respond to any adverse inspectional observations or product safety issues, or if any corrective action plan that we or our suppliers propose in response to observed deficiencies is not sufficient, the FDA or foreign regulatory authorities could take enforcement action, including any of the following sanctions:
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
This evolution may create uncertainty in our business, affect our or our collaborators', service providers' and contractors' ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
If the cost of key components or raw materials increases and we are unable to fully recover those increased costs through price increases or offset these increases through other cost reductions, we could experience an adverse effect on our results of operations and financial condition.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we do not achieve significant sales of these new/transitioned products, it might be necessary for us to recognize an impairment charge for the value of the production tooling because its costs may not be recovered through production of saleable product, which could adversely affect our financial condition.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
In particular, we We expect the DPF Adequacy Decision existing legal complexity and uncertainty regarding international personal data transfers to be challenged continue, and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
There can also be no assurance that our and our third-party service providers’, strategic partners’, contractors’, consultants’, CROs’ and collaborators’ cybersecurity risk management program and processes, including policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems, networks and Confidential Information.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
While we may from time to time engage in various initiatives (including but not limited to voluntary disclosures, policies or goals) to improve our ESG profile or respond to certain stakeholder expectations, we cannot guarantee that these initiatives will have the desired effect.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Such laws and regulations will be are subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Increased tariffs could require us to increase our prices, which likely could decrease demand for our products, and in certain many cases we may be unable to pass along increased costs to our customers if they are under long-term fixed price contracts.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
patient monitoring, and temperature management products. We also offer IV Solutions products through a commercial relationship with the joint venture.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
The U.S. administration has continued to engage in trade discussions and impose tariffs on imports from other countries. Certain of these tariffs have been subsequently paused or modified, and the situation remains highly fluid. For example, on July 31, 2025, the U.S. announced that the 10% baseline reciprocal tariff on imports from all countries would be raised to 15% for certain countries, including Costa Rica. More recently, the U.S. administration threatened to impose additional tariffs on European allies as a penalty for the Greenland dispute. In response, the European Union prepared a list of retaliatory tariffs; subsequently, the U.S. withdrew the proposed tariffs following diplomatic discussions.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
The majority of our global revenues are from products manufactured in our Costa Rica and Mexico manufacturing facilities and imported into the U.S. Currently the vast majority of products manufactured in our Mexico facilities are exempted from tariffs under the United States-Mexico-Canada Agreement ("USMCA"). If, however, the USMCA exemptions were eliminated in the future, our tariff expense for products manufactured in Mexico would increase substantially. The tariffs as currently implemented are likely to have a material impact on our business, financial condition and results of operations through the incurrence of additional costs; however, the extent to which the imposition of tariffs, possible delays and exemptions may have a material impact remains fluid. During 2025, we incurred $33.6 million in incremental reciprocal tariffs as a result of the tariffs imposed by the U.S. Administration in 2025, of which $7.9 million was capitalized and $25.7 million was expensed.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
In September 2025, the U.S. Commerce Department (the "Department") initiated a national security investigation into imports of medical consumables and equipment under Section 232 of the Trade Expansion Act (the "Act"). The Act allows the President to negotiate tariffs to promote international trade. Section 232 of the Act specifically grants the President the authority to impose tariffs if the Department determines imports threaten U.S. national security. The Department has 270 days to deliver its policy recommendations to the President, who then has up to 90 days to decide on potential action and 15 days to implement it. If the probes conducted determine these imports, which comprise the vast majority of our product portfolio, pose a national security risk, it could result in potential tariffs imposed in addition to the country-based tariffs and/or could reduce the benefits we receive from currently available exemptions such as the USMCA.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Based on current geopolitical conditions we expect foreign currency rates, freight costs, oil prices, interest rates, and general inflation to remain subject to volatility in the market.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Disposition of our IV Solutions Business and Prepayment of a portion of our Long-term Obligations
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On April 24, 2025, pursuant to a purchase agreement (the "Agreement") with Otsuka Pharmaceutical Factory America, Inc. a Delaware corporation ("OPF") (described in Note 3: Assets Held For Sale and Disposal of Business to our accompanying consolidated financial statements), we completed the formation of ICU Medical Pearl LLC (n/k/a Otsuka ICU Medical LLC (the "joint venture")) and transferred the assets, liabilities and operations that comprise our IV Solutions product line to the joint venture. At the closing of the transaction on May 1, 2025, under the Agreement, we sold a 60% interest in the joint venture to OPF. The total sales price, inclusive of our final price adjustments, was $211.2 million, of which we used $200.0 million of the proceeds from the sale to pay down a portion of our outstanding Term Loan A (as defined below) long-term debt during the second quarter of 2025.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
In addition to comparing changes in revenue on a U.S. GAAP basis, we also compare the changes in revenue from one period to another using constant currency. The presentation of revenues on a constant currency basis is a non-GAAP financial
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Vital Care revenue decreased in 2025, as compared to 2024, primarily due to lower IV Solutions sales of $213.9 million as a result of the sale of a controlling ownership interest in our IV Solutions business on May 1, 2025 (see Note 3: Assets Held For Sale and Disposal of Business to our accompanying consolidated financial statements).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Consolidated SG&A expenses decreased in 2025, as compared to 2024, primarily due to a decrease of $9.8 million in depreciation and amortization, $5.9 million in bad debt and warranty expense, and $5.5 million in compensation costs which when combined with other smaller category decreases, were partially offset by an increase of $8.3 million in stock based compensation and $4.9 million in professional services. Depreciation and amortization expense decreased primarily due to the disposal of certain assets related to the sale of a 60% interest of our IV Solutions business (see Note 3: Assets Held For Sale and Disposal of Business to our accompanying consolidated financial statements). Bad debt expense is adjusted quarterly, if deemed necessary, based on an assessment of our accounts receivables and our expectations regarding the collectability of those accounts. Warranty expense decreased due to the release of reserves related to certain products and lower warranty estimated reserve due to lower warranty claims expected. Compensation costs decreased primarily due to service fee income recorded in the same line as the related personnel expenses for services provided to the joint venture (see Note 3: Assets Held For Sale and Disposal of Business to our accompanying consolidated financial statements). Stock based compensation increased due to a change in the probability of meeting certain financial targets related to a performance equity award. Professional services increased primarily due to higher costs related to the use of third-party service providers supporting various projects and initiatives.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Additionally, interest expense during 2025 includes the interest accretion on an unfavorable contract loss provision and a loss on debt extinguishment due to a debt refinancing which we completed in October 2025, (see Note 12: Long-Term Obligations in our accompanying consolidated financial statements).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
The interest expense component decreased in 2025, as compared to 2024, primarily due to decrease in the applicable SOFR reference rate and due to lower obligation principal balances. During 2025 we prepaid $35.0 million on our Term Loan B in March 2025, $200.0 million on our Term Loan A in May 2025 using proceeds from the sale of a 60% interest of our IV Solutions business, $25.0 million on our Term Loan B in September 2025, and $30.0 million on our Term Loan B in December 2025. Additionally, the October 2025 debt refinance reduced borrowing costs in the last part of the year as $190.0 million of the lower rate Term Loan A issuance was used to settle a portion of the higher rate Term Loan B in a cashless roll.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedMD&A
catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
We also continue to expect higher interest rates and volatility in foreign currency rates due to the strengthening of the U.S. dollar against most global currencies. Our 2024, 2023 and 2022 financial results were negatively impacted by foreign exchange losses and our results of operations may continue to be impacted in the future.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
More recently, in January 2025, the current administration issued executive orders imposing tariffs on imported goods from Canada, Mexico, and China. In response, Canada announced similar tariffs on U.S. imports. A meaningful portion of our global revenues are from products manufactured in our Mexico manufacturing facilities and imported into the U.S. In addition, Canada is our second largest country in terms of revenue and the vast majority of products sold in Canada are imported from the U.S. The 25% tariff levied on all goods shipped from Mexico to the U.S., combined with the 25% tariff on products shipped from the U.S. to Canada could potentially have a meaningful impact to our costs and any further trade war escalation could increase that impact.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Vital Care revenue decreased in 2023, as compared to 2022, primarily due to lower sales volume of IV Solutions which was impacted by supply disruptions related to finished good products purchased from third-party manufacturers and lower sales volume for products acquired from Smiths Group plc ("Smiths") due to backorder recovery in 2022.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
On January 6, 2022, we acquired Smiths Medical. We financed the $1.9 billion cash portion of the purchase price at closing with a combination of proceeds from the Senior Secured Credit Facilities and our cash and cash equivalents. See Note 2: Acquisitions and Note 13: Long-Term Obligations in our accompanying consolidated financial statements for additional information.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
(2) Our business acquisitions will vary from period to period based upon our current growth strategy and our ability to execute on desirable target companies. In 2022, we acquired Smiths Medical. The cash consideration for the transaction was $1.9 billion, which was financed with existing cash balances and borrowings under the Credit Agreement. Acquired cash was $78.8 million.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
(3) Our purchases of investment securities will vary from period to period based on current cash needs, planning for known future transactions and changes in our investment strategy. Our investment policy allows for the purchase of securities with final maturities in excess of one year. If cash is not needed for known future transactions our investment strategy takes advantage of the long-term securities with higher yields. Typically, our longer term securities have maturities up to three years.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Proceeds from issuance of long-term debt, net of lender debt issuance costs $ — $ — $ 1,664,362 $ — $ (1,664,362) (1)
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
(2) Relates to scheduled principal payments on the Senior Secured Credit Facilities.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
The application of the acquisition method of accounting for business combinations requires the use of significant estimates, assumptions and judgments in the determination of the estimated fair value of assets acquired and liabilities assumed in order to properly allocate the purchase price at the acquisition date.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Although we believe the estimates, assumptions and judgments we have made are reasonable, they are based in part on historical experience, industry data, information obtained from the management of the acquired companies and assistance from independent third-party appraisal/valuation firms, and are inherently uncertain.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Examples of critical estimates in valuing certain of the tangible and intangible assets we have acquired, and certain liabilities assumed include but are not limited to:
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
Percentage of Revenues 2025 2024 2023 2022 Total revenues 100% 100% 100% Gross profit 37% 35% 33% 31% Selling, general and administrative expenses 27% 28% 27% 27% Research and development expenses 4% 4% 4% Restructuring, strategic transaction and integration expenses 3% 3% 2% 3% Change in fair value of contingent earn-out —% (1)% —% (1)% Total operating expenses 35% 34% 32% 33% Income from operations 2% 1% 1% (2)% Interest expense, net (4)% (4)% (3)% (4)% Other expense, net —% (1)% —% Gain on sale of business 2% —% Loss —% Income (Loss) before income taxes and equity in losses of unconsolidated affiliates —% (4)% (3)% (5)% Provision (benefit) (Provision) benefit for income taxes —% 2% (2)% (2)% Net loss income (loss) from consolidated affiliates —% (6)% (1)% (3)% Equity in losses of unconsolidated affiliates —% —% —% Net income (loss) —% (6)% (1)%
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
We In recent years, we have experienced experienced, and may continue to experience experience, significant impacts to our business as a result of global economic challenges, resulting from, among other events, health pandemics and geopolitical conflicts. conflicts which have resulted in fluctuating inflation rates, especially with respect to increased cost and shortages of raw materials, supply chain disruptions, higher interest rates, volatility on foreign currency exchange rates, and freight costs driven by higher fuel prices.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The changes in operating assets and liabilities included Offsetting these amounts was a $201.1 $26.3 million increase in inventories, a $21.3 $11.0 million increase in prepaid expenses and other current assets, a $7.0 million increase in other assets, a $55.8 $37.0 million decrease in accrued liabilities, $66.7 and $24.8 million in net changes in income taxes, including excess tax benefits and deferred income taxes, and a $19.2 million increase in accounts receivable. taxes.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Due to the weight of objectively verifiable negative evidence, the Company recorded a change to the valuation allowance of $81.7 million tax expense and $3.9 million foreign currency translation and derivative instrument adjustments against certain U.S. federal and state deferred tax assets assets, resulting in a $8.7 million tax expense and $2.8 million foreign currency translation and derivative instrument adjustments, for the tax years ending December 31, 2024. 2025.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The Credit Agreement provides for amended credit facility includes a new five-year term loan A facility of $850.0 $750.0 million (the "Term Loan A"), a seven-year term loan B facility of $850.0 million (the "Term Loan B") and a new five-year revolving credit facility of $500.0 million (the "Revolving Credit Facility") (collectively, the "Senior Secured Credit Facilities"). Facility").
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, $ change % change $ change % change 2025 2024 2023 2022 2025 over 2024 2024 over 2023 2023 over 2022 Consumables revenue (GAAP) $ 1,038.9 1,109.2 $1,038.9 $969.1 $975.0 $ 70.3 6.8% $ 69.8 7.2% $ (5.9) (0.6)% Impact of foreign exchange rate changes (6.6) 2.8 $4.0 Consumables revenue on a constant currency basis (non-GAAP) $ 1,041.7 $973.1 1,102.6 $1,041.7 $ Change in constant currency $ 72.6 $(1.9) 63.7 $72.6 % Change in constant currency 7.5 6.1 % (0.2)% 7.5%
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, $ change % change $ change % change 2025 2024 2023 2022 2025 over 2024 2024 over 2023 2023 over 2022 Infusion Systems (GAAP) $ 652.4 684.2 $652.4 $629.0 $617.4 $ 31.8 4.9% $ 23.4 3.7% $ 11.6 1.9% Impact of foreign exchange rate changes (1.3) 20.3 $10.5 Infusion Systems on a constant currency basis (non-GAAP) $ 672.7 $639.5 682.9 $672.7 $ Change in constant currency $ 43.7 $22.1 30.5 $43.7 % Change in constant currency 6.9 4.7 % 3.6% 6.9%
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The Additionally, the effective tax rate in 2024 2025 included a tax benefit of $10.1 $7.1 million primarily related to unrecognized tax benefits released as a result of the expiration of the statute of limitations offset by a tax expense of $81.7 million related to a valuation allowance against certain U.S. federal and state deferred tax assets. limitations.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
In 2024, 2025 we incurred $40.2 $36.5 million in strategic transaction and integration expenses primarily related to consulting expenses and employee costs incurred to integrate our Smiths Medical business acquired in 2022. 2022, and transaction costs related to the sale of a 60% interest of our IV Solutions business in the second quarter of 2025.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The foreign exchange losses gains, net in 2024 2025 were primarily related to the strengthening weakening of the U.S. dollar relative to certain foreign currencies, including the Euro and British Pound, partially offset by the weakening of the U.S. dollar relative to the Mexican peso and Argentine peso. Peso.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
During 2024, 2025, our cash and cash equivalents and short-term investment securities increased decreased by $53.8 $0.6 million from $254.7 million at December 31, 2023 to $308.6 million at December 31, 2024. 2024 to $308.0 million at December 31, 2025.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The primary drivers for the net decrease in accrued liabilities was primarily due to payments for field corrective actions, operating lease liabilities and distributor rebates as well as a decrease in deferred revenue offset partially by increases in accrued employee costs.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new